US imposes 100% tariff on imported pharmaceuticals, targeting Australia and global exporters
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025, targeting global exporters including Australia. The move, enacted under Section 232 of the Trade Expansion Act, bypasses a February 2025 Supreme Court ruling that invalidated Trumpâs broader 'Liberation Day' tariffs. Australia, which exported approximately $1.3â$2 billion in pharmaceuticals to the US in 2025, faces potential disruptions, though CSLâa major exporter with US manufacturing facilitiesâmay qualify for exemptions or reduced tariffs due to its domestic production. The tariff applies only to patented drugs, not generics, and offers incentives for companies to relocate production to the US, reducing tariffs to 20% or eliminating them entirely if pricing deals are struck. Countries like the EU, Japan, and the UK have secured lower tariff rates through trade deals, while Australia lacks such protections. The US administration argues the tariffs are necessary for national security, aiming to reshoring drug production amid concerns over global supply chains. Australian officials, including Health Minister Mark Butler, have rejected pressure to alter the countryâs Pharmaceutical Benefits Scheme (PBS), which subsidizes lower drug prices than in the US, calling it a cornerstone of healthcare. Opposition Leader Angus Taylor has pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters. The move reflects broader tensions over international drug pricing and manufacturing policies, with implications for global trade and healthcare affordability.
â Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025.
- Australia exported $US1.32bn (or approximately $US1.3bnâ$US2bn depending on source) in pharmaceuticals to the US in 2025, with CSL (Melbourne-based) accounting for the bulk of these exports.
- The tariff applies only to patented drugs, not generic medicines, and is enacted under Section 232 of the Trade Expansion Act, unaffected by the February 2025 US Supreme Court ruling on 'Liberation Day' tariffs.
- CSL has US manufacturing facilities in Illinois and North Carolina, with a $US2.2bn (or $US1.5bn in other sources) expansion project underway in Illinois, set to complete by 2031.
- Companies moving production to the US can reduce tariffs to 20%, and those securing 'most favoured nation' drug pricing deals with the US can avoid tariffs entirely.
- Australiaâs Pharmaceutical Benefits Scheme (PBS) subsidizes drug prices lower than those in the US, which the Trump administration has criticized as undermining 'most favoured nation' pricing rules.
- Japan, the EU, South Korea, Switzerland, and Liechtenstein face 15% tariffs, while the UK has negotiated a 10% tariff with potential for future reductions to zero.
- Health Minister Mark Butler stated Australia would not negotiate changes to the PBS, calling it 'fundamental' to Australian healthcare and affordable for patients.
- Opposition Leader Angus Taylor (Coalition) pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters.
- The US executive order includes exemptions for plasma-derived therapies if they meet urgent US health needs or come from countries with trade deals with the US.
Points of Difference
Details reported by only one source:
- CSLâs bulk of Australian exports are made in Melbourne, but the company has invested heavily in US manufacturing to mitigate tariff risks.
- The tariff applies to patented products only, not generic medicines, and the US Supreme Court ruled in February that Trumpâs 'Liberation Day' tariffs were illegal, but this pharmaceutical levy was enacted under different legislation.
- The US Supreme Court ruling did not cover the pharmaceutical tariffs because they were enacted under Section 232 of the Trade Expansion Act, not emergency powers.
- The tariff was invoked under national security powers, with Trump stating it was necessary to address 'threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients'.
- The executive order mentions that companies like AstraZeneca have already struck specific deals with the White House to lower US prices and avoid tariffs.
- Medicines Australia warned that 'most favoured nation' rules are hampering new medicine imports to Australia, with companies delaying or avoiding launches due to low Australian prices.
- The tariff announcement was timed to mark one year since Trumpâs 'Liberation Day' tariffs (February 2025), which were later struck down by the Supreme Court.
- Smaller companies have 180 days to comply with tariffs, while larger companies have 120 days, with new facilities needing completion by January 2029 (end of Trumpâs term).
- The tariff adjustment for steel-containing products was mentioned: if a product has less than 15% steel, the additional tariff is set to zero, but other tariffs still apply.
- Health Minister Mark Butler called the decision 'deeply disappointing and deeply concerning' in a direct quote.
- The tariff is the latest challenge for Australian manufacturers selling products to American consumers, with the White House trying to force changes to Australiaâs PBS.
- The Guardian explicitly states that Trumpâs plan is expected to exempt generic drugs and maintain more favorable tariff rates for drugs produced in the EU, Japan, South Korea, and Switzerland.
- The article repeats details from SMH and NEWSCOMAU verbatim, with no additional unique information.
- A senior administration official told the ABC that Trump had previously threatened a 200% tariff, but it was ultimately set at 100%.
- The ABC reported that Trumpâs tariff is designed to protect domestic pharmaceutical production for national security reasons, citing concerns about global conflicts or pandemics.
- The ABC noted that CSL had previously stated in September 2024 that it did not expect any material impact from the tariffâs implementation, despite earlier threats.
- The ABC included a direct quote from a senior administration official: 'While we research and we develop them, and we're the innovators and we are the patent holders, we've allowed other countries to make the drugs â and therefore were beholden to these other countries.'
Contradictions
Conflicting information between sources:
- NEWSCOMAU and ABC report that Trump previously threatened a 200% tariff, but only ABC explicitly states this was mentioned in a social media post from September 2024.
- NEWSCOMAU states CSLâs bulk of Australian exports are made in Melbourne, while ABC and SMH emphasize CSLâs significant US manufacturing presence and expansion projects.
- NEWSCOMAU reports the tariff applies to patented products only, not generic medicines, but ABC does not explicitly mention this distinction.
- SMH and ABC mention that smaller companies have 180 days to comply, but NEWSCOMAU does not specify this distinction between large and small companies.
- The Guardian states the tariff is expected to exempt generic drugs, but NEWSCOMAU does not mention this explicitly, only stating it applies to patented products.
Source Articles
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Australia says it wonât raise drug prices after Trumpâs 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ânot negotiatingâ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump imposes 100 per cent tariff on Australian drugs â but with caveats
Australiaâs largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump imposes 100 per cent tariff on Australian drugs â but with caveats
Australiaâs largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....